Evidence map›Paper›PMID 32977230›Full record

ArticleJournal of the neurological sciences2020

Lack of APOE Christchurch variant in five age of onset outliers with PSEN1, PSEN2 Alzheimer's disease and MAPT frontotemporal dementia.

Chang-En Yu, Sunny Chen, Suman Jayadev, Thomas Bird

Open access · greenAbstract read
In one paragraph

Article in Journal of the neurological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Chang-En YuDepartments of Medicine, University of Washington, VA Puget Sound Health Care System, United States of America; Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, United States of America.
Sunny ChenGeriatric Research Education and Clinical Center, VA Puget Sound Health Care System, United States of America.
Suman JayadevDepartments of Neurology, University of Washington, VA Puget Sound Health Care System, United States of America.
Thomas BirdDepartments of Neurology, University of Washington, VA Puget Sound Health Care System, United States of America; Departments of Medicine, University of Washington, VA Puget Sound Health Care System, United States of America; Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, United States of America. Electronic address: tomnroz@uw.edu.
VA Puget Sound Health Care System · USGeriatric Research Education and Clinical Center · USUniversity of Washington · US

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Thomas J. Grabowski · 2020 to 2026
$29.0M
APOE Gene-Based Haplotype Study in Alzeheimer's DiseaseR21AG024486 · NIA · UNIVERSITY OF WASHINGTON · PI YU, CHANG-EN · 2004 to 2005
$225k
The role of APOE locus genes regulation in Alzheimer's diseaseI01BX000933 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI YU, CHANG-EN · 2011 to 2024
–
Genetic Studies of Neurologic and Dementing DisordersI01CX001006 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI BIRD, THOMAS DWIGHT · 2014 to 2017
–
BLRD VA I01 BX000933BLRD VA I01 BX004823CSRD VA I01 CX001006NIA NIH HHS P30 AG066509NIA NIH HHS P50 AG005136NIA NIH HHS R21 AG024486
6 · The paper itself

Abstract

introductionAge of onset modifiers are of considerable importance in Alzheimer's and related dementias. Arboleda-Valesquez et al., reporting on a single PSEN1 subject, suggested that homozygosity for the Christchurch variant of APOE could represent such a modifier.

methodsWe studied APOE Christchurch and Kloth-VS genotypes of five dementia age of onset outliers who carried their families' pathogenic variant, but were asymptomatic at ages beyond the families' average age of onset.

resultsFour age of onset outliers with PSEN1/2 and MAPT mutations did not carry the Christchurch variant and a fifth individual was also determined to not be homozygous for this variant. Among them, only one subject (APOE ε3/ε3) carries the Klotho-VS heterozygous genotype. DISCUSSION: From a small but informative sample of five age of onset outliers we show that neither the APOE Christchurch nor the Klotho-VS variant is a common age of onset modifier for three genetic forms of dementia. Larger studies of this association and further research is required to identify additional genetic modifiers.

Indexed as

Alzheimer DiseaseFrontotemporal DementiaAge of OnsetApolipoproteins EHumansMutationPresenilin-1Presenilin-2tau ProteinsApolipoproteins EMAPT protein, humanPresenilin-1Presenilin-2PSEN1 protein, humanPSEN2 protein, humantau ProteinsAlzheimer's diseaseAPOEChristchurch mutationDementiaModifiers

Identifiers

PMID32977230
PMCPMC7606829
OpenAlexW3087415963

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.